UK markets closed

CureVac N.V. (CVAC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
89.93-2.91 (-3.13%)
As of 1:16PM EST. Market open.

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
49 7071 9883 0

Full-time employees500

Key executives

NameTitlePayExercisedYear born
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.CEO, COO & Member of Management BoardN/AN/A1970
Dr. Florian von der Mulbe M.B.A., Ph.D., MBACo-Founder, Member of Management Board & Chief Production OfficerN/AN/A1973
Mr. Pierre Kemula B.Sc.CFO & Member of Management BoardN/AN/A1974
Ms. Mariola Fotin-MleczekCTO & Member of Management BoardN/AN/A1968
Dr. Igor Splawski M.Sc., Ph.D.Chief Scientific Officer & Member of Management BoardN/AN/A1969
Dr. Ingmar HoerrCo-Founder, CEO & Supervisory Board Chairman (Leave of Absence)N/AN/AN/A
Dr. Bernd Winterhalter M.D., Ph.D.Interim Chief Devel. OfficerN/AN/A1959
Dr. Sarah FakihVP of Investor RelationsN/AN/AN/A
Mr. Thorsten SchüllerHead of Corp. CommunicationsN/AN/AN/A
Slavica Stevanovic-HeckHead of HRN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others, as well as a collaboration with the U.K. Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.